Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry

Abstract

Listen

Translate article

The DAPT score identifies patients with expected benefit from extended dual antiplatelet therapy beyond 1year after percutaneous coronary intervention (PCI). In a post-hoc analysis from the AFCAS registry, we explored the value of DAPT score to predict outcome in patients with atrial fibrillation (AF) undergoing PCI. Outcome measures included major adverse cardiac/cerebrovascular events (MACCE) [all-cause death, myocardial infarction, repeat revascularization, stent thrombosis, or stroke/transient ischemic attack] and bleeding events. At 12-month follow-up, patients with a DAPT score≥1 had a higher incidence of MACCE, all-cause death, myocardial infarction (p=0.004, p=0.006, and p=0.013, respectively), but a similar bleeding rate (p=0.66), versus those with a DAPT score <1. In a subgroup of patients at high risk of stroke who received triple therapy for 1month only, DAPT score ≥1 was associated with a higher incidence of MACCE, all-cause death, myocardial infarction (p=0.002, p=0.015, and p=0.039, respectively), but a similar bleeding rate (p=0.81). In AF patients undergoing PCI, a DAPT score ≥1 was associated with a higher incidence of thrombotic events, and a similar incidence of bleeding events, compared with a DAPT score <1. These results were consistent in patients at high risk of stroke who received triple therapy for 1month.